Report: Healthcare, regulatory and reimbursement landscape - Mexico

Friday, September 14, 2012 11:28 AM

Industry analysis specialist GlobalData has released its new report, Healthcare, Regulatory and Reimbursement Landscape – Mexico, which identifies the key trends in the Mexican healthcare market, as well as providing insights on the demographic, regulatory and reimbursement landscape, and the healthcare infrastructure of Mexico.

Most importantly, the report provides valuable insights on the trends and segmentation of the pharmaceutical and medical devices market. This report is built using data and information sourced from proprietary databases, secondary research and in-house analysis by a team of industry experts.

The population of Mexico in 2010 was approximately 112 million and was the 11th-most populated country in the world, and is increasing due to the country's high birth rate and increase in life expectancy.

The pharmaceutical market in Mexico was estimated at $11.4 billion in 2010 and is expected to reach approximately $22.5 billion by 2020 at a projected CAGR of 7%. The medical device market size was approximately $3 billion in 2010 and is expected to reach approximately $4.9 billion by 2020 at a projected CAGR of 5.2%.

According to GlobalData’s report, the positive trend in the Mexican healthcare market can be attributed primarily to an increasing elderly population; government initiatives for the prevention and management of chronic diseases; the North American Free Trade Agreement, which guarantees its members the protection of intellectual property rights; and an improved and updated regulatory environment.

The report provides information on the healthcare, regulatory and reimbursement landscape of Mexico. Its scope includes an overview of the Mexican pharmaceutical and medical devices market including the market size, market segmentation, key drivers and barriers for the market. It also includes a profile and SWOT analysis of the major players in the pharmaceutical and medical devices market—Pfizer, Sanofi and Genomma Lab, F. Hoffmann-la Roche, Siemens Healthcare and Fresenius Medical.

In addition, the scope includes review on the reimbursement and regulatory landscape. Analysis includes details of the healthcare reimbursement process, regulatory agencies and market authorization process for new drug and medical devices for Mexico; a details of the political and economic environment of Mexico including economic indicators, demographics, healthcare infrastructure and healthcare expenditure; and an overview of the opportunities and challenges for growth that exist in the Mexican healthcare market.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

August 25

Verizon Communications enters clinical trial space with technology, network, and cloud and data services

Sponsors look to the power of genomic profiling to screen, enroll patients in trials for targeted therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs